You are adding an alert for:
Real-life outcomes of switching AntiVEGF treatment from ranibizumab to aflibercept for neovascular agerelated macular degeneration (nAMD): UK multicentre study.
You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
The alert will be sent to: